Precision BioSciences Inc (DTIL) - Total Liabilities
Based on the latest financial reports, Precision BioSciences Inc (DTIL) has total liabilities worth $62.17 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore DTIL operating cash flow to assess how effectively this company generates cash.
Precision BioSciences Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Precision BioSciences Inc's total liabilities have evolved over time, based on quarterly financial data. Check DTIL financial resilience to evaluate the company's liquid asset resilience ratio.
Precision BioSciences Inc Competitors by Total Liabilities
The table below lists competitors of Precision BioSciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
United Security Bancshares
NASDAQ:UBFO
|
USA | $1.11 Billion |
|
DNF Co.Ltd
KQ:092070
|
Korea | ₩8.13 Billion |
|
Bonei Hatichon Civil Engineering and Infrastructures Ltd
TA:BOTI
|
Israel | ILA1.25 Billion |
|
Inveo Yatirim Holding AS
IS:INVEO
|
Turkey | TL1.68 Billion |
|
Kyungbangco.Ltd
KO:000050
|
Korea | ₩442.38 Billion |
|
Jyoti Structures Limited
NSE:JYOTISTRUC
|
India | Rs24.15 Billion |
|
Protalix Biotherapeutics Inc
NYSE MKT:PLX
|
USA | $29.36 Million |
|
Aumann AG
XETRA:AAG
|
Germany | €108.40 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Precision BioSciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DTIL market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Precision BioSciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Precision BioSciences Inc (2016–2025)
The table below shows the annual total liabilities of Precision BioSciences Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $62.17 Million | -22.29% |
| 2024-12-31 | $80.00 Million | -43.23% |
| 2023-12-31 | $140.92 Million | -20.71% |
| 2022-12-31 | $177.74 Million | +47.71% |
| 2021-12-31 | $120.33 Million | +13.81% |
| 2020-12-31 | $105.73 Million | +9.09% |
| 2019-12-31 | $96.92 Million | -1.74% |
| 2018-12-31 | $98.64 Million | -0.41% |
| 2017-12-31 | $99.05 Million | -3.99% |
| 2016-12-31 | $103.16 Million | -- |
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalent… Read more